In short
Forecast unchanged- First-half revenue was ¥175 million, down 12.5% year on year.
- The operating loss widened to ¥498 million due to costs related to the transfer of production, among other factors.
- The company outlined a policy of building a foundation for medium- to long-term growth through approval for recurrent meningioma and expansion into mainland China.
What they reported
this period against the same period a year earlier, and where they now expect the year to endSales
| Period | ¥bn |
|---|---|
| FY25 Q1 | 0.1 |
| FY25 Q2 | 0.1 |
| FY25 Q3 | 0.1 |
| FY25 Q4 | 0.7 |
| FY26 Q1 | 0.1 |
| FY26 Q2 | 0.1 |
| FY26 Q3 | 0.1 |
| FY26 Q4 | 0.1 |
| FY27 Q1 | 0.1 |
| FY27 Q2 | 0.1 |
First-half revenue declined 12.5% year on year.
当上期の売上高は、前年同期比12.5%減の175百万円となりました。Operating profit
| Period | ¥m |
|---|---|
| FY25 Q1 | -166.0 |
| FY25 Q2 | -103.0 |
| FY25 Q3 | -106.0 |
| FY25 Q4 | 285.0 |
| FY26 Q1 | -151.0 |
| FY26 Q2 | -147.0 |
| FY26 Q3 | -214.0 |
| FY26 Q4 | -236.0 |
| FY27 Q1 | -245.0 |
| FY27 Q2 | -253.0 |
Although the gross profit margin was at the same level as in the prior-year period, the operating loss widened as outsourcing expenses related to the transfer of production increased.
売上総利益率は前年同期と同水準を維持したものの、生産移管に関連する業務委託費の増加等により、営業利益は△498百万円となりました。Ordinary profit
| Period | ¥m |
|---|---|
| FY25 Q1 | -161.0 |
| FY25 Q2 | -106.0 |
| FY25 Q3 | -104.0 |
| FY25 Q4 | 234.0 |
| FY26 Q1 | -155.0 |
| FY26 Q2 | -151.0 |
| FY26 Q3 | -203.0 |
| FY26 Q4 | -269.0 |
| FY27 Q1 | -228.0 |
| FY27 Q2 | -239.0 |
The company recorded ¥53 million in subsidy income, among other items, as non-operating income.
一方、補助金収入53百万円を営業外収益として計上したことなどから、経常利益は△467百万円、中間純利益は△469百万円となりました。Net profit
| Period | ¥m |
|---|---|
| FY25 Q1 | -161.0 |
| FY25 Q2 | -107.0 |
| FY25 Q3 | -105.0 |
| FY25 Q4 | 233.0 |
| FY26 Q1 | -156.0 |
| FY26 Q2 | -151.0 |
| FY26 Q3 | -205.0 |
| FY26 Q4 | -268.0 |
| FY27 Q1 | -228.0 |
| FY27 Q2 | -241.0 |
The interim net loss was ¥469 million, mainly due to ¥53 million in subsidy income, among other factors.
一方、補助金収入53百万円を営業外収益として計上したことなどから、経常利益は△467百万円、中間純利益は△469百万円となりました。Their own numbers
figures this company chose to report, a year ago against nowThe estimated patient population for recurrent meningioma in Japan is approximately 4,000.
The patient population in China is estimated at approximately 15,000.
The patient population in Europe is estimated at approximately 35,000.
The planned number of cases for the domestic Phase I/II trial is 30.
BNCT treatment began in March 2026 at the Hainan Island Medical Special Zone.
The low–high ranges are Komori's estimate, not figures the company gave.
Everything else in the deck
What moved
New initiatives
- The company will transfer production to a new manufacturing company and proceed with an application to add a manufacturing site, rebuilding a stable supply system.
- The company will allocate funds to clinical trials for rare cancers and research and development for deep-seated cancers.
- The company aims to obtain approval and build a sales structure in mainland China by using real-world clinical data from Hainan Island.
- The company will establish a business framework for joint development, regulatory filings and sales with its Chinese partner.
What decks usually leave out
COMPUTED = worked out by Komori from reported numbers; the rest are stated in this deckProgress toward the full-year forecast
¥0.2bn earned of the ¥1.0bn forecast.
The rest of the year has to bring in ¥0.9bn, −27 pts off the usual pace.
| Period | % |
|---|---|
| FY23 | 40% |
| FY24 | 57% |
| FY25 | 18% |
| FY26 | 62% |
| FY27 | 17% |
Margins and overheads
Overheads (selling and admin costs): ¥643.6m
Financial targets
| Period | % |
|---|---|
| FY22 | -46.4 |
| FY23 | -26.7 |
| FY24 | -29.8 |
| FY25 | -5.0 |
| FY26 | -27.7 |
| FY27 | -22.0 |
| Period | % |
|---|---|
| FY22 | 65.3 |
| FY23 | 63.3 |
| FY24 | 62.0 |
| FY25 | 59.2 |
| FY26 | 54.1 |
| FY27 | 59.2 |
Yearly figures are computed by Komori from J-Quants results data (ROE = net profit ÷ average equity). The last point is this year's forecast or latest figure. Targets show only when this deck states them.